# Isa-VRdlite for of Frail and/or Much Older Patients With High Risk Newly Diagnosed Multiple Myeloma Base on Circulating Plasma Cells

> **NCT07732712** · PHASE2,PHASE3 · NOT_YET_RECRUITING · sponsor: **The Affiliated People's Hospital of Ningbo University** · enrollment: 15 (estimated)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** Isatuximab
- **DRUG:** VRD

## Key facts

- **NCT ID:** NCT07732712
- **Lead sponsor:** The Affiliated People's Hospital of Ningbo University
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2027-01-01
- **Primary completion:** 2028-12-31
- **Final completion:** 2030-12-31
- **Target enrollment:** 15 (ESTIMATED)
- **Last updated:** 2026-10-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07732712

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07732712, "Isa-VRdlite for of Frail and/or Much Older Patients With High Risk Newly Diagnosed Multiple Myeloma Base on Circulating Plasma Cells". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07732712. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*